Compare Novartis AG (NVS) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Victoria's Secret & Co — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Victoria's Secret & Co trades at $87.3 (market cap $6.91B). The key difference: Novartis AG is far larger — about 38.9× Victoria's Secret & Co's market cap, and Novartis AG pays a 3.31% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Victoria's Secret & Co for 34 Days on average.
| NVS | VSXY | |
|---|---|---|
Market Cap | $268.57B | $6.91B |
Volume | 1,532,573 | 1,346,928 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $99.97 |
52-Week Low | $121.80 | $28.25 |
Typical Hold Time | 82 Days | 34 Days |
Enterprise Value | $309.89B | $9.29B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Victoria's Secret (VSXY) trades at $85.79, up 0.83% today, with a bullish technical trend and strong analyst support. Recent earnings beats and a 60% buy rating from analysts highlight improving fundamentals, while the stock shows robust profitability with a 45.27% ROE. The company's 2026 revenue guidance raise and global expansion efforts signal positive momentum, though valuation remains elevated with a P/E of 19.15.
The outlook for VSXY is positive, driven by earnings growth and brand revitalization, but risks include rich valuation and competitive pressures. Upside to the $86.80 consensus target appears achievable if execution continues, yet investors face margin volatility and macroeconomic sensitivity in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
